Besides identifying molecular targets, the molecular investigation of AML subtypes can also evaluate genetic alterations that are associated with enhanced or decreased responses to chemotherapy that targets apoptotic pathways (e.g., mitochondrial apoptosis), identifying mechanisms that modulate sensitivity to these chemotherapeutic options, including Bcl-2 inhibitors that are referred to herein [28]. The gene discussed is BCL2; the disease is acute myeloid leukemia.